Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment

Benjamin Nicholson, Jason Noble, Farzin Forooghian, Catherine Meyerle

Research output: Contribution to journalReview articlepeer-review

Abstract

Recent technological advances-new pathophysiological insights, new imaging techniques for diagnosis and management, and new treatments-have led to an improved understanding of central serous chorioretinopathy (CSC). The primary role of the choroid has become more widely accepted with widespread use of indocyanine green angiography. Optical coherence tomography (OCT), and particularly enhanced depth imaging OCT, demonstrate a thickened and engorged choroid. Adaptive optics, fundus autofluorescence, multifocal electroretinography, microperimetry, and contrast sensitivity testing reveal that patients with even a mild course suffer previously undetected anatomic and functional loss. Although focal laser and photodynamic therapy are the current standard of care for persistent subretinal fluid in CSC, they are not appropriate in all cases, and the optimal timing of intervention remains unclear.

Original languageEnglish (US)
Pages (from-to)103-126
Number of pages24
JournalSurvey of ophthalmology
Volume58
Issue number2
DOIs
StatePublished - Mar 2013

Keywords

  • Central serous chorioretinopathy
  • Corticosteroids
  • Diffuse retinal pigment epitheliopathy
  • Fundus autofluorescence
  • Indocyanine green angiography
  • Optical coherence tomography
  • Photodynamic therapy

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment'. Together they form a unique fingerprint.

Cite this